Researchers developed a strategy combining urinary albumin:creatinine ratio (UACR) and glomerular filtration rate (GFR) slope to predict treatment effects on patient outcomes. This approach improved predictions in phase 2 clinical trials with sample sizes of 100–200 patients per arm or follow-up times ranging between 1 and 2 years.
The COVID-19 pandemic has significantly increased the mortality risk of hemodialysis patients, with risks persisting at higher levels for those with confirmed infections. Other patients on dialysis experienced slightly elevated mortality risk during peak pandemic periods.
A new decision support tool used in emergency departments has been shown to reduce 30-day all-cause death or cardiovascular hospitalization rates by 12% in heart failure patients. The validated tool, developed using data analytics, helps clinicians determine risk categories and inform admission or discharge decisions.
A recent analysis of COVID-19 cases in four waves found that individuals with chronic kidney disease were more likely to develop severe forms of COVID-19 and experience complications. Pre-existing conditions, including CKD, were consistent clinical predictors of COVID-19 severity across multiple pandemic waves.
Researchers from Tokyo Metropolitan University developed a VR system that enables users to share their visual and sensory experiences on Segways with remote collaborators. The system reduced VR sickness by 54% and improved user experience, promising new possibilities for remote collaboration.
Patients with advanced kidney disease may benefit from conservative non-dialytic management over dialysis for hospitalization prevention. Patients of Asian ethnicity show the highest hospitalization rates on early dialysis compared to late dialysis or conservative management. Conservative management underutilized in US due to uncertain...
A major randomized trial of pemafibrate found no reduction in rates of heart attack, stroke, or cardiovascular death over a five-year period, despite lowering triglycerides by 26 percent. Pemafibrate was effective at reducing remnant cholesterol levels but failed to demonstrate clinical benefits.